Начальный рак молочной железы. Спорные вопросы по больным раком молочной железы in situ

Обложка

Цитировать

Полный текст

Аннотация

Совершенствование скрининга рака молочной железы (РМЖ) путем внедрения цифровой маммографии повысило обнаружение начальных форм опухоли, на стадии in situ, до 25% случаев от всех выявляемых РМЖ. Это привело к хирургическому или комбинированному лечению в 98% случаев, хотя риск прогрессирования в инвазивный рак наблюдался лишь у 50-75% больных. В этой связи поиск маркеров прогноза и степень радикализма лечения для таких пациенток - сегодня самые обсуждаемые вопросы клинических дискуссий. Предлагаем наш взгляд на проблему начальных раков молочной железы и выработку оптимального подхода в лечении.

Об авторах

Валентина Васильевна Косый

ФНКЦ ФМБА России

врач-онколог онкологического отделения ФНКЦ ФМБА

Анна Генриховна Кедрова

ФНКЦ ФМБА России

Email: kedrova.anna@gmail.com
д.м.н., профессор, зав. онкологическим отделением ФНКЦ ФМБА России

Список литературы

  1. Nekhlyudov L, Habel LA, Achacoso N, et al. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012;104: 614-621
  2. Cancer facts and figures 2015. Breast Carcinoma In situ. 2015. Atlanta: American Cancer Society; 2015. pp.26-37
  3. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ [published online August 20, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.2510.
  4. Cuzick J, Sestak I, Cawthorn S, et al; IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67-75.
  5. Morrow M., Schnitt Stuart J., Norton L. //Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol. 2015, 12, 237-8.
  6. Provenzano E, Hopper JL, Giles GG et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003; 39: 622-30.
  7. Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer 2011; 2: 232-261
  8. Solin L, Gray R, Baehner FL, Butler S et al. A prospective validation study of the DCIS score from ECOG E5194. Cancer Res 2011; 71: 41.
  9. Lee H.S. Use of Immunohistochemistry in the Diagnosis of Problematic Breast Lesions. J Clin Pathol. 2013;66(6):471-477.
  10. Barnes, A. Cramer, R. Johnson, K.Cheema, et al. Bundred Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Onc 2015 May 1; 26(5): 1019 -25.
  11. Esserman L., Yau C., Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2015 DOI: 10,1001 / jamaoncol.2015.2607.
  12. Guillot E, Vaysse C, Goetgeluck J, Falcou M.C., Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. Breast. 2014 Apr;23(2):97-103. doi: 10.1016/j.breast.2013.12.002.
  13. American Cancer Society. Lifetime risk of developing or dying from cancer. Revised October 1, 2014. http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer. Accessed June 25, 2015.
  14. Luo J, Cochrane BB, Wactawski-Wende J, Hunt JR, Ockene JK, Margolis KL. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013;137: 915-925
  15. Margolese RG, Cecchini RS, Julian TB, et al. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Am Soc Clin Oncol. 2015;33(suppl):abstr LBA500
  16. Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010: 162-177.
  17. National Comprehensive Cancer Network. Breast Cancer (Version 3.2014 October,2014). Available from URL www.nccn.org/professionals/ physician_gls/pdf/breast.pdf
  18. Rakovitch E., Nofech-Mozes S., Hanna W., et.al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Research and Treatment, July 2015, Volume 152, Issue 2, pp 389-398.
  19. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-98
  20. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-87.
  21. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56: 1038-45.
  22. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57: 75-89
  23. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009; 27: 1362-1367
  24. Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guidepractice? World J of Clin Onco. 2014;5: 546-553
  25. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data. J Clin Oncol. 2005;23: 5534-5541
  26. Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a populationbased analysis. Ann Surg Oncol. 2013;20: 3240-46.
  27. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57: 75-89.
  28. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30: 1268-73.

© Косый В.В., Кедрова А.Г., 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах